Clinical trials for Squamous cell carcinoma of the hypopharynx
11 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT07063212A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)Memorial Sloan Kettering Cancer Center · PI: Winston Wong, MD
- RECRUITINGPhase 1NCT06761937Thermoradiotherapy for Locally Advanced Head and Neck Cancer PatientsErasmus Medical Center · PI: Michiel Kroesen, MD, Dr.
- RECRUITINGPhase 3NCT06706401Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck CarcinomaCentre Leon Berard · PI: Vincent Grégoire, PhD
- RECRUITINGNCT06380686Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and OutcomeAIO-Studien-gGmbH · PI: Victor Grünwald, Prof. Dr.
- RECRUITINGPhase 3NCT06525220A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Merus B.V.
- RECRUITINGPhase 3NCT05333523Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.Radboud University Medical Center
- RECRUITINGPhase 2NCT04858269First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma PatientsWake Forest University Health Sciences · PI: Thomas Lycan, DO
- ACTIVE NOT RECRUITINGPhase 3NCT04590963Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerAstraZeneca · PI: Roger B Cohen, MD
- RECRUITINGPHASE2, PHASE3NCT01810913Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck CancerNational Cancer Institute (NCI) · PI: Paul M Harari
- RECRUITINGN/ANCT01473784Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and NeckOhio State University Comprehensive Cancer Center · PI: Enver Ozer, MD
- ACTIVE NOT RECRUITINGPhase 2NCT00494182Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell CancerM.D. Anderson Cancer Center · PI: George Blumenschein, MD